研究单位：[1]Jiangsu HengRui Medicine Co., Ltd.[2]The Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China河北医科大学第四医院[3]The Second Xiangya Hospital of Central South University Changsha, Hunan, China[4]The Second Affiliated Hospital of Soochow University Suzhou, Jiangsu, China[5]Northern Jiangsu People's Hospital Yangzhou, Jiangsu, China, 225001[6]Shengjing Hospital of China Medical University Shenyang, Liaoning, China, 110004[7]Qilu Hospital of Shandong University Jinan, Shandong, China, 250012[8]Taizhou Hospital Taizhou, Zhejiang, China[9]Xuan Wu hospital affiliated to Capital Medical University Beijing, China, 100053[10]Beijing Tongren hospital affiliated to Capital Medical University Beijing, China, 11691777[11]Longhua Hospital Shanghai University of Traditional Chinese Medicine Shanghai, China[12]Gansu Provincial Hospital Lanzhou, Gansu, China
The aim of present study is to evaluate the efficacy and safety of Extended-Release Carvedilol Sulfate versus in Patients With Mild or Moderate Primary Hypertension
